Search PubMed⌕ Search

Biomedical subjects

R Moses

Publications and source records attributed to R Moses.

At least 19 recordsLinked to original sources

Second-trimester intra-abdominal bowel dilation in fetuses with gastroschisis predicts neonatal bowel atresia.

OBJECTIVE: To determine in fetuses with gastroschisis the association between intra-abdominal bowel dilation in the second trimester and neonatal bowel atresia. METHODS: We reviewed ultrasound and medical records of fetuses with gastroschisis from January 1998 to August 2004. Fetuses with intra-abdominal bowel dilation in the second trimester were identified and followed into the neonatal period. RESULTS: We identified 58 mother-infant pairs showing fetal gastroschisis, with at least one prenatal ultrasound at our hospital and which were delivered there, or were transported there as newborns. Forty-eight of the 58 fetuses had no intra-abdominal bowel dilation and none of these neonates had bowel atresia. Ten of the 58 fetuses had intra-abdominal bowel dilation and all had bowel atresia at birth (P<0.0001). In eight cases in which ultrasound was performed at <25 weeks' gestation, intra-abdominal bowel dilation was already present. CONCLUSION: Intra-abdominal bowel dilation in the second trimester predicts neonatal bowel atresia in fetuses with gastroschisis.

Dilatation, Pathologic↗

Repaglinide in combination therapy.

Type 2 diabetes mellitus (T2DM) is a progressive disorder requiring increasingly aggressive treatment to achieve and maintain target blood glucose concentrations in the presence of deteriorating insulin secretion and increasing insulin resistance. Diet and lifestyle modification are often sufficient initially; however, most patients eventually require pharmacological intervention. With disease progression, monotherapy becomes less effective, so combination therapy is required, using drugs with complementary modes of action to maximise glycaemic control. The prandial glucose regulator repaglinide has been studied in combination with metformin (an inhibitor of hepatic glucose production), neutral protamine Hagedorn (NPH)-insulin (which has a long duration of effect, but at the risk of early hypoglycaemia and late hyperglycaemia in the dosing interval) and three thiazolidinediones (TZDs--troglitazone, rosiglitazone and pioglitazone, which stimulate nuclear receptors to increase insulin sensitivity and reduce insulin resistance) in patients whose diabetes was inadequately controlled by previous monotherapy or combination therapy. The combination of repaglinide and metformin resulted in reduced fasting plasma glucose concentrations (by 2.2 mmol/l) and HbA1c (by 1.4%). Combination therapy with repaglinide and bedtime NPH-insulin resulted in reductions in fasting plasma glucose (by 5.4 mmol/l) and HbA1c (by 0.7%). The combination of repaglinide and each TZD also resulted in consistent decreases in fasting plasma glucose concentrations and HbA1c. No severe hypoglycaemic episodes were reported in the three studies. In conclusion, repaglinide has additive, and often synergistic, effects on glycaemic control when given in combination regimens and should be a valuable option in the management of patients with T2DM.

Carbamates↗

Positional cloning of a novel Fanconi anemia gene, FANCD2.

Fanconi anemia (FA) is a genetic disease with birth defects, bone marrow failure, and cancer susceptibility. To date, genes for five of the seven known complementation groups have been cloned. Complementation group D is heterogeneous, consisting of two distinct genes, FANCD1 and FANCD2. Here we report the positional cloning of FANCD2. The gene consists of 44 exons, encodes a novel 1451 amino acid nuclear protein, and has two protein isoforms. Similar to other FA proteins, the FANCD2 protein has no known functional domains, but unlike other known FA genes, FANCD2 is highly conserved in A. thaliana, C. elegans, and Drosophila. Retroviral transduction of the cloned FANCD2 cDNA into FA-D2 cells resulted in functional complementation of MMC sensitivity.

Alleles↗

Gingival, dermal, and periodontal ligament fibroblasts express different extracellular matrix receptors.

BACKGROUND: Fibroblasts are the predominant cells of the periodontal ligament and the gingiva and have important roles in the function and regeneration of the tooth support apparatus. The goal of this study was to investigate the possible differences in the adhesion properties and expression of extracellular matrix (ECM) receptors among different fibroblast populations. METHODS: The adhesion of gingival (GF), dermal (DF), and periodontal ligament fibroblast (PDLF) cultures to ECM proteins (fibronectin, laminin, vitronectin, RGD peptide, collagen type I, and collagen type IV) adsorbed to tissue culture plastic was evaluated fluorometrically. Quantitative reverse transcription-polymerase chain reactions (RT-PCR) were performed using primers specific for 19 integrin subunits to quantify ECM receptor transcript expression. RESULTS: Our data demonstrated that GF and PDLF adhere to vitronectin and collagen types I and IV more avidly than do DF. PDLF adhered well to laminin, whereas GF and DF did not. Quantitation of integrin expression demonstrated that the different fibroblast types expressed different integrin transcripts, further demonstrating their innate differences. CONCLUSIONS: The 3 fibroblast types studied behave differently and expressed different ECM receptors. However, gingival fibroblasts and periodontal ligament fibroblasts are more similar in their attachment and integrin expression than either is to dermal fibroblasts. Therefore, experiments using DF will not necessarily be valid for oral tissues.

Cell Adhesion↗

The putative collagen binding peptide hastens periodontal ligament cell attachment to bone replacement graft materials.

BACKGROUND: Bone replacement graft (BRG) materials are often used to treat periodontal defects, to promote cellular invasion, and to encourage bone regrowth. Periodontal ligament fibroblasts (PDLF) incorporate these materials and form the basis of the renewed connection between the existing and newly formed alveolar bone and the tooth surface. A peptide (P-15) that mimics the putative cell-binding domain of collagen has been reported to promote dermal fibroblast attachment and proliferation. METHODS: PDLF were quantitatively examined for their ability to adhere to a variety of BRG materials fluorometrically. In addition, scanning electron microscopy was used to examine the changes in morphology exhibited by these cells as they attached and spread on several BRG materials. Finally, BRG materials containing the P-15 peptide were quantitatively examined for their ability to promote PDLF attachment and proliferation. RESULTS: Freeze-dried allograft bone supports greater PDLF attachment than does several xenograft and alloplastic anorganic bone replacement materials. An anorganic BRG material containing the P-15 peptide promoted more rapid cell attachment and spreading than a similar anorganic BRG material lacking this peptide. Finally, none of the BRG materials examined promoted PDLF proliferation. CONCLUSIONS: Our data indicate that the addition of the P-15 peptide increases the rapidity of PDLF attachment to xenogeneic bone replacement materials. This increase in the rate of attachment may have clinical significance in the context of the dynamic regulation of cell attachment during periodontal regeneration. However, this peptide does not promote an increase in stable cell attachment or proliferation in vitro.

Animals↗

A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.

Repaglinide is a novel insulin secretagogue that was developed as a prandial glucose regulator for the treatment of people with Type 2 diabetes mellitus. It is used flexibly, taken prior to meals, in order to limit subsequent postprandial blood glucose excursions as well as the dependent basal blood glucose concentration. In theory, the pharmacological profile of repaglinide is well suited for this role. Taken at mealtimes, its relatively rapid-onset and short-duration of action counteract a fundamental pathophysiological aspect of this disease: attenuation of the prandial insulin response. The predominantly hepatic elimination profile and a lack of drug-drug interactions with repaglinide are also properties well suited for patients with Type 2 diabetes. Importantly, the pharmacokinetic properties of repaglinide, are expected to reduce the risk of hypoglycaemia in comparison to the conventional insulin secretagogues (sulphonylureas). A reduced risk of hypoglycaemia carries the advantage that patients are not obliged to consume meals at regular intervals supplemented by snacks, so caloric restriction is feasible and lifestyle not compromised. These theoretical advantages have now been largely borne-out by clinical studies and empirical experience. Placebo-controlled studies have consistently demonstrated the antidiabetic efficacy of repaglinide, with improvements having been shown in all indicators of glycaemic control. Double-blind, active-comparator studies have shown repaglinide to have an antidiabetic efficacy that is at least equivalent to sulphonylureas, even when food intake and dosing intervals were controlled according to the requirements of sulphonylureas. Pooled data from these studies have shown that the risk of severe hypoglycaemia is reduced by 60% (p = 0.03) when repaglinide is used in preference to sulphonylureas. There is also evidence that the blood glucose threshold at which symptoms of hypoglycaemia are perceived by patients may be better preserved during treatment with repaglinide than with sulphonylureas. Studies examining flexible prandial dosing with repaglinide have shown that good glycaemic control and a low risk of hypoglycaemia are achievable goals that are independent of the meal (and, hence, dosing) pattern chosen by the patient. Furthermore, when used in this way, repaglinide has not been associated with weight gain. In combination therapy, repaglinide has been shown to act in synergy with both metformin and troglitazone. The possibility of a 'new' basal-bolus regimen combining repaglinide and exogenous (neutral protamine hagedorn) NPH insulin strategy has also been investigated.

Blood Glucose↗

Repaglinide in combination therapy with metformin in Type 2 diabetes.

Results are presented of a double-blind, Australian multicentre study of the efficacy and safety of adjunctive repaglinide in patients with Type 2 diabetes who were controlled inadequately on metformin monotherapy. Patients had to have been on metformin for at least 6 months and to have glycated haemoglobin (HbA1c) levels of more than 7.1%. Patients were randomized to one of three treatment regimens: metformin plus placebo (MET, n = 27), repaglinide plus placebo (REP, n = 29) and metformin plus repaglinide (MET/REP, n = 27). The metformin dose remained unchanged from the prestudy dose, whereas repaglinide was titrated from 0.5 mg to 4.0 mg preprandially, depending on fasting capillary blood glucose concentration. Maintenance treatment was continued for 3 months. In the MET and REP groups, the HbA1c level decreased from 8.6% to 8.3% and from 8.6% to 8.2%, respectively; in the MET/REP group, HbA1c decreased from 8.3% to 6.9% (p < 0.001 vs. baseline; p < 0.05 vs. each monotherapy group). Overall, 59% of patients in the MET/REP group achieved a HbA1c level of less than 7.1% by the end of the study, compared with 20% and 22% in the MET and REP groups, respectively. No serious adverse events occurred that were considered to be related to study medication. Mild symptoms of hypoglycaemia were seen in the REP and MET/REP groups, in many cases during the titration phase. The combination of repaglinide with metformin was safe and well tolerated and produced a greater improvement in glycaemic control than that seen by the sum of the changes with the two agents alone.

Australia↗

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

OBJECTIVE: To compare the effect of repaglinide in combination with metformin with monotherapy of each drug on glycemic control in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 83 patients with type 2 diabetes who had inadequate glycemic control (HbA1c > 7.1%) when receiving the antidiabetic agent metformin were enrolled in this multicenter, double-blind trial. Subjects were randomized to continue with their prestudy dose of metformin (n = 27), to continue with their prestudy dose of metformin with the addition of repaglinide (n = 27), or to receive repaglinide alone (n = 29). For patients receiving repaglinide, the optimal dose was determined during a 4- to 8-week titration and continued for a 3-month maintenance period. RESULTS: In subjects receiving combined therapy, HbA1c was reduced by 1.4 +/- 0.2%, from 8.3 to 6.9% (P = 0.0016) and fasting plasma glucose by 2.2 mmol/l (P = 0.0003). No significant changes were observed in subjects treated with either repaglinide or metformin monotherapy in HbA1c (0.4 and 0.3% decrease, respectively) or fasting plasma glucose (0.5 mmol/l increase and 0.3 mmol/l decrease respectively). Subjects receiving repaglinide either alone or in combination with metformin, had an increase in fasting levels of insulin between baseline and the end of the trial of 4.04 +/- 1.56 and 4.23 +/- 1.50 mU/l, respectively (P < 0.02). Gastrointestinal adverse events were common in the metformin group. An increase in body weight occurred in the repaglinide and combined therapy groups (2.4 +/- 0.5 and 3.0 +/- 0.5 kg, respectively; P < 0.05). CONCLUSIONS: Combined metformin and repaglinide therapy resulted in superior glycemic control compared with repaglinide or metformin monotherapy in patients with type 2 diabetes whose glycemia had not been well controlled on metformin alone. Repaglinide monotherapy was as effective as metformin monotherapy.

Australia↗

The converging roads of HIM and managed care.

The authors explore the definition of managed care and how the health information manager's skills apply to a managed care setting. In addition, HIM professionals who have made the transition to the managed care setting share their experiences.

Career Mobility↗

[Repaglinide in combination therapy in type 2 diabetes].

In addition to dietary and lifestyle changes, standing as the cornerstone of type 2 diabetes care, pharmacological treatments, whether as single or multidrug patterns, are often necessary for an efficient blood glucose control. Besides insulin, four different oral antidiabetic drug categories are available, each of them acting through different and potentially synergistic ways. Oral antidiabetic drugs include: 1) biguanides acting through the reduction of hepatic glucose production and are most efficient in obese patients; 2) alpha-glucosidase inhibitors delaying carbohydrate intestinal absorption; 3) thiazolidinediones or "glitazones", acting as insulin sensitizers; 4) insulin secretion enhancers, mainly including sulfonylureas, which increase insulin secretion and are being credited by a long clinical usage; these are now joined by the new generation of insulin secretion enhancers, led by repaglinide, which can mimic the physiological insulin secretion profile by a specific stimulatory effect on beta-cells characterized by its fast onset and short half-life. Obviously, the combination of these different antidiabetic drugs, by targetting different synergistic and additive pathways, can help to further improve blood glucose.

Carbamates↗

The metabolic profile of glucose tolerant women who have had large for gestational age babies.

The possibility has been raised that women who have had large for gestational age infants, while glucose tolerant during pregnancy by conventional testing, may still have a subtle abnormality of carbohydrate metabolism. We have examined, some time after the completion of a pregnancy, the fasting levels of glucose, insulin and lipids in a group of women, glucose tolerant during pregnancy, who had a large for gestational age infant compared to a very carefully matched control group of women who had an appropriate for gestational age infant. No significant differences were found. These findings suggest that women who have a large for gestational age infant do so for a variety of reasons not related to maternal carbohydrate metabolism.

Blood Glucose↗

Gestational diabetes mellitus; resource utilization and costs of diagnosis and treatment.

The recommendation to test every woman for gestational diabetes mellitus (GDM) has a defined cost. The management of women diagnosed with GDM will use additional health resources. This examines the cost and resource utilization of a consecutive group of women diagnosed over a 1-year period. The cost of testing a woman for GDM is around $10.00 with slight variations depending on the testing procedure. The annual cost of testing in NSW would be less than 1 million dollars. Women diagnosed with GDM used the resources of a diabetes education centre for an average of 2.8 hours and attended for 3.4 (2.3) medical visits. Insulin was required by 18.7% of the women for 9.7 (4.7) weeks using 47.7 (21.2) units each day. Testing women for GDM is a low-cost item. Managing a woman diagnosed with GDM may cost several hundred dollars. Cost reductions could be made by reducing the amount of insulin used and by avoiding hospitalization.

Costs and Cost Analysis↗

Predominance of a maternal history of diabetes for patients with non-insulin-dependent diabetes mellitus. Implications for the intrauterine transmission of diabetes.

In Europid populations, patients with non-insulin-dependent diabetes mellitus (NIDDM) are more than twice as likely to have a mother than a father with diabetes. We have examined this aspect in an Australian population. For this purpose records of 1,000 consecutive patients with NIDDM were reviewed. A history of diabetes was present in 193 mothers (19.3%) and in only 86 fathers (8.6%) (p < 0.0001). The predominance of maternal history of diabetes in patients with NIDDM is suggestive of a maternal transmission of this disorder. This metabolic tendency may develop due to an adverse intrauterine environment in women with undiagnosed gestational diabetes mellitus.

Adult↗

The accuracy of home glucose meters for the glucose range anticipated in pregnancy.

Home glucose meters are used almost universally for the management of pregnant women with diabetes. However, the degree of accuracy of meters in general and particularly for the lower glucose range, is questionable. Six of the most commonly used meters in Australia were evaluated for analytical accuracy for glucose levels < 8.0 mmol/L--a level below which many important clinical management decisions are made. Two meters, Elite and Precision QID, cannot be recommended. The other 4 meters, Glucometer 3, Reflolux S, Alpha and Advantage produced results with a higher degree of analytical accuracy. Of the meters tested, the Accutrend Alpha had the highest proportion of results within 5% and 10% of a laboratory reference method, the lowest bias with the Altman Bland method of comparison, and is recommended for use in pregnancy. No meter approached the analytical accuracy goal recommended by the American Diabetes Association. Manufacturers should be encouraged to develop or adapt systems for use in pregnancy.

Adult↗

Vertical impact forces during bench-step aerobics: exercise rate and experience.

The purpose of this study was to determine the effects of two bench-step exercise speeds on vertical impact forces and to explore this variable between novices, and instructors. 12 women (mean age 24 yr.) randomly performed 8-min. protocols of the "basic" bench-stepping technique and a more advanced "travel" technique at 30 and 33 cycles.min.-1. Analysis showed that the faster exercise rate yielded significantly higher vertical impact forces on a reference (B-8) step height (20.3 cm). At 33 cycles.min.-1, the instructors, and novices' responses were both higher than those at 30 cycles.min.-1. The mean peak vertical impact force ranged from 1.54 times the body weight for the novice group at 30 cycles.min.-1 to 1.87 times the body weight for instructors at 33 cycles.min.-1. A comparison of the groups' force curves showed a distinctive pattern in the loading of the impact forces. Specifically, the instructors consistently produced a transitory decrement in force prior to attaining peak force. In addition, the novices exhibited nonuniform increases in the production of vertical impact force across other step heights at the faster (33 cycles.min.-1) speed. Thus, experience with bench-step exercise may afford an ability to make uniform and force-absorbing adjustments in the resultant vertical impact forces at increased speeds.

Adult↗